title: Potential first-in-class osteoporosis drug speeds through trials.
authors.forename: Sarah C P
authors.initials: SC
authors.lastname: Williams
mesh_terms: D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D056657:Cathepsin K / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001713:Biphenyl Compounds; D004791:Enzyme Inhibitors; D056657:Cathepsin K; C527128:odanacatib